CRAMS Major Swings to ₹9 Crore Loss from ₹86.7 Crore Profit a Year Ago as Revenue Falls 16%; Investors Dump Stock Amid Weak Business Outlook

Shares of Syngene International Ltd. came under heavy selling pressure on Thursday after the company reported a disappointing set of first-quarter results for FY27, posting a quarterly loss for the first time in several years. The stock plunged over 9%, touching a fresh 52-week low, as investors reacted to declining revenue, weaker operational performance and exceptional employee separation costs.

The sharp fall highlights the challenges currently facing India's contract research and manufacturing services (CRAMS) industry, where slower global biotech funding, cautious pharmaceutical spending and temporary business disruptions have impacted growth across several companies.

Stock Crashes to Fresh One-Year Low

Syngene International witnessed intense selling pressure from the opening bell following the release of its June quarter earnings.

Share Price Performance

• Shares opened sharply lower at ₹391 on the NSE.

• The stock declined to an intraday low of ₹375.25, marking a fresh 52-week low.

• Around 9:30 AM, it was trading at ₹377.80, down nearly 8.8%.

• Nearly 20 lakh shares changed hands in early trade, indicating strong institutional and retail participation in the sell-off.

The decline extends the stock's prolonged correction, with investor sentiment remaining weak after the disappointing quarterly performance.

Company Reports Loss in Q1 FY27

Syngene's earnings deteriorated significantly during the April-June quarter as lower business activity and one-time restructuring expenses weighed on profitability.

Q1 FY27 Financial Performance

The company reported a consolidated net loss of ₹9 crore, compared with a net profit of ₹86.7 crore in the corresponding quarter of the previous financial year.

Revenue also declined sharply, reflecting weaker demand across parts of its research and manufacturing business.

Exceptional Employee Separation Costs Impact Bottom Line

A significant contributor to the quarterly loss was the recognition of ₹13.5 crore towards employee termination benefits.

The company classified this amount under exceptional items, indicating that the expense is non-recurring.

However, even after adjusting for the one-time charge, the decline in revenue suggests that operational performance remained under pressure during the quarter.

Revenue Declines as Business Activity Slows

Revenue from operations declined nearly 16% year-on-year, falling to ₹736 crore from ₹874.5 crore in the corresponding quarter last year.

The lower revenue indicates:

• Reduced project activity.

• Slower research outsourcing demand.

• Softer contribution from certain customer segments.

• Lower capacity utilisation.

The decline in revenue also impacted operating leverage, resulting in weaker profitability.

Why Did Investors React So Sharply?

Although a part of the quarterly loss was due to one-time restructuring costs, investors were more concerned about the sharp decline in the company's core business performance.

Key Reasons Behind the Sell-Off

• Revenue declined by nearly 16%.

• Company reported a quarterly loss instead of profit.

• Lower operating leverage impacted margins.

• Weak demand environment.

• Exceptional employee separation costs.

• Limited visibility on near-term earnings recovery.

The results have increased concerns regarding the pace of recovery in the global CRAMS industry.

Technical Charts Continue to Signal Weakness

Market technicians believe the stock remains in a firmly established downtrend.

According to technical analysts:

• The stock continues to form lower highs and lower lows, indicating sustained selling pressure.

• The ₹400–395 range had emerged as a key support zone.

• The recent breakdown below this level could trigger another round of weakness if buying interest does not return.

Until a meaningful reversal is seen, the technical outlook remains bearish.

About Syngene International

Syngene International is one of India's leading Contract Research, Development and Manufacturing Services (CRAMS) companies.

The company provides end-to-end research, development and manufacturing solutions to global pharmaceutical, biotechnology and healthcare companies.

Its operations cover:

• Drug discovery research.

• Clinical development.

• Biologics research.

• Contract manufacturing.

• Commercial manufacturing.

• Analytical services.

The company serves several multinational pharmaceutical companies and biotechnology firms across global markets.

Industry Faces Near-Term Challenges

The global CRAMS industry has witnessed moderation in growth over the past few quarters.

Some of the key reasons include:

• Lower funding for biotechnology companies.

• Delayed research programmes.

• Cost optimisation by pharmaceutical companies.

• Global macroeconomic uncertainty.

• Slower outsourcing decisions.

Despite these near-term challenges, the industry's long-term structural growth drivers remain intact.

Long-Term Growth Drivers Continue to Support the Business

Several structural trends continue to favour companies operating in the CRAMS space.

Growth Opportunities

• Increasing outsourcing by global pharmaceutical companies.

• Expansion of biologics manufacturing.

• Growing demand for contract development services.

• Rising R&D expenditure over the long term.

• China+1 supply chain diversification.

• Increasing demand for integrated research services.

As global pharmaceutical companies diversify their manufacturing and research partnerships, Indian CRAMS companies are expected to benefit over the longer term.

Key Risks Investors Should Watch

While the long-term outlook remains favourable, investors should closely monitor several factors.

Major Risks

• Continued slowdown in global biotech funding.

• Delays in large client projects.

• Pressure on research outsourcing budgets.

• Margin compression.

• Rising employee costs.

• Lower capacity utilisation.

• Weak commercial manufacturing demand.

Management's ability to secure new contracts and improve utilisation levels will be critical for earnings recovery.

What Investors Should Track Going Forward

The next few quarters will be crucial for assessing the company's turnaround.

Investors should monitor:

• Quarterly revenue growth.

• Order inflows from global clients.

• Capacity utilisation.

• Margin recovery.

• New commercial manufacturing contracts.

• Management guidance.

• Progress in reducing exceptional costs.

Improvement across these metrics will be necessary to restore investor confidence.

Market Outlook

Syngene International's disappointing Q1 results are likely to keep sentiment subdued for the stock in the near term, particularly after the company reported its first quarterly loss in several years. The sharp decline in revenue, coupled with exceptional restructuring costs, has raised concerns about demand recovery in the global contract research and manufacturing industry. Investors are expected to remain cautious until the company demonstrates sustained improvement in revenue growth and profitability.

From a broader market perspective, however, the long-term outlook for India's CRAMS sector remains positive. Global pharmaceutical companies continue to increase outsourcing, biologics manufacturing is expanding and the China+1 strategy continues to create opportunities for Indian research and manufacturing companies. Investors should closely monitor Syngene's upcoming quarterly performance, client additions, commercial manufacturing pipeline and management's demand outlook. A recovery in these areas could improve sentiment not only for Syngene but also for the broader pharmaceutical services sector.